Archives

  • 2018-07
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04
  • 2024-05
  • 2024-06
  • 2024-07
  • The nAChR has been considered an

    2024-07-09

    The α7 nAChR has been considered an interesting potential target for numerous therapeutic indications over the last two decades, with GTS-21 one of the first candidates proposed for Alzheimer's disease [2], [3], [23]. Unfortunately, although many α7-selective agonists have been developed [21], none have made it JWH 015 successfully through clinical trials for cognitive disorders, although small-scale trials continue with GTS-21 and schizophrenia [24]. Appreciation for the potential importance of the cholinergic anti-inflammatory pathway as an avenue for treating diverse indications such as asthma, arthritis, and neuropathic pain has redirected the field to search for different kinds of drugs for these different sorts of diseases, and insulin may be that attention will shift toward drugs like NS6740 that were once dismissed as an “anti-therapeutic” for cognition.
    Acknowledgements This work was supported by National Institutes of Health Grants GM57481 and AG052258, and the Evelyn F. McKnight Brain Research Foundation. We thank Dr. Michael King for technical assistance in the LTP experiments. We thank Dr. Ganesh Thakur (Northeastern University) for gift of the NS6740.